Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen’s bone cancer drug XGEVA, used to ...

In a website posting, the International Generic and Biosimilar medicines Association (IGBA) has commended the General ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

Imexpharm Pharmaceutical JSC (IMP) expects to complete procedures by September to begin construction of its Cat Khanh ...

South Korean biopharmaceutical firm Celltrion announced Thursday that it has signed a second major deal with one of the top five pharmacy benefit managers in th ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar development business to streamline its operations and focus on its core contract ...

In the dim basement of a Salt Lake City pharmacy, hundreds of amber-colored plastic pill bottles sit stacked in rows, one man ...

Moving on to AVT04, our biosimilar to Stelara, we continue to build on the strong launch of this biosimilar under the UZPRUVO brand with STADA in Europe. In Europe, we were the first to market ...

BENGALURU/HYDERABAD May 8 (Reuters) - Indian biopharma firm Biocon's (BION.NS), opens new tab profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar ...